Delta-Fly Pharma, Inc.(4598) News

Delta-Fly Pharma rises for fifth straight day on planned FDA talks for DFP-10917

Notice Regarding Preparations for Discussions with the U.S. FDA on DFP-10917 Monotherapy and Combination Therapy with Venetoclax

Delta-Fly Pharma Rises for Third Straight Day on Increased Stake by Macquarie Bank

Notice Regarding Partial Corrections and Inquiries Regarding the Announcement Regarding the DMC on the P1／2 of DFP-10917+VEN

Announcement Regarding the Data Monitoring Committee Decision on the Phase 1/2 Study of DFP-10917 combination with Venetoclax in Relapsed or Refractor

Follow up Interim analysis for Phase 3 Study of DFP-10917

Delta-Fly Pharma, Apr-Dec (Cumulative 3Q) Net Income Loss Narrows, Oct-Dec Net Income Loss Widens

Update DFP-10917 combo-therapy with VEN

Update for DFP-10917 related clinical studies

Delta-Fly Pharma, First Half Net Income Loss Narrows, Jul-Sep Net Income Loss Widens

Progress status of DFP-10917 involved clinical studies

First Patient Enrolled in Phase 2/3 Randomized Study of DFP-17729 for Pancreatic Cancer in Japan

Delta-Fly Pharma, Apr-Jun (1Q) Net Income Loss Narrows

Progress status for Phase 1/2 study of DFP-10917 with Venetoclax (VEN) in the 2nd line AML

Delta-Fly Pharma, The Current Fiscal Year's Net Income to Narrow

Announcement of novel patent filing for the DFP-10917 drug product

Announcement for a phase 2/3 study of DFP-17729 to be started

Delta-Fly Pharma, Apr-Dec (Cumulative 3Q) Net Income Loss Widens, Oct-Dec Net Income Loss Widens

Delta-Fly Pharma, Inc., First Half Net Income Loss Widens, July-September Net Income Loss Widens